RLFTY (Relief Therapeutics Holding) 5-Year Share Buyback Ratio : -17.70% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Relief Therapeutics Holding 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Relief Therapeutics Holding's current 5-Year Share Buyback Ratio was -17.70%.

RLFTY's 5-Year Share Buyback Ratio is ranked worse than
66.41% of 1155 companies
in the Biotechnology industry
Industry Median: -9.9 vs RLFTY: -17.70

Competitive Comparison of Relief Therapeutics Holding's 5-Year Share Buyback Ratio

For the Biotechnology subindustry, Relief Therapeutics Holding's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding's 5-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's 5-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Relief Therapeutics Holding 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Relief Therapeutics Holding (OTCPK:RLFTY) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Relief Therapeutics Holding 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTY) » Definitions » 5-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

RLFTF:USA RLFz:UK 0QKQ:UK V6M:Germany RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.